Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05748600 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma
A Phase 3 study of Asthma Attack and Eosinophilic Asthma, sponsored by Areteia Therapeutics.
- Active
- Registry status
- Phase 3
- Development phase
- 600
- Enrollment target
- 20
- Study locations
NCT05748600 is a Phase 3 study of Asthma Attack and Eosinophilic Asthma that is active but no longer recruiting, run by Areteia Therapeutics. The registered enrollment target is 600 participants, below the 833-participant average among 4 other Asthma Attack trials with a reported enrollment target (28% lower). The trial reports 20 study locations across 2 states.
The verdict
NCT05748600, a Phase 3 study of Asthma Attack and Eosinophilic Asthma, is active but no longer recruiting, sponsored by Areteia Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 600 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate dexpramipexole as an add-on oral therapy in participants with inadequately controlled eosinophilic asthma to evaluate improvements in lung function, asthma control, and quality of life. In addition, the study will further evaluate the safety and tolerability of dexpramipexole in participants with eosinophilic asthma.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Dexpramipexole Dihydrochloride
Study Locations (20)
California
- Research Site 40001-374 - Bakersfield
- Research Site 40001-227 - Encinitas
- Research Site 40001-349 - Huntington Beach
- Research Site 40001-485 - Inglewood
- Research Site 40001-440 - La Palma
- Research Site 40001-357 - Lancaster
- Research Site 40001-089 - Los Angeles
- Research Site 40001-362 - Mission Viejo
- Research Site 40001-449 - Napa
- Research Site 40001-062 - Newport Beach
- Research Site 40001-043 - Newport Beach
- Research Site 40001-380 - Redding
- Research Site 40001-434 - San Diego
- Research Site 40001-088 - San Jose
- Research Site 40001-359 - Upland
- Research Site 40001-003 - West Covina
- Research Site 40001-419 - Westminster
Arizona
- Research Site 40001-487 - Chandler
- Research Site 40001-462 - Peoria
- Research Site 40001-322 - Surprise
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2023-01-30 |
| Est. Completion | 2025-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05748600
The ClinicalTrials.gov registry entry for NCT05748600 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 833-participant average among 4 other Asthma Attack trials with a reported enrollment target (28% lower). The listed sponsor is Areteia Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Asthma Attack appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05748600 reports 20 study locations spanning 2 distinct geographic areas - top geographies include California, Arizona.
Frequently Asked Questions
What is clinical trial NCT05748600 about?
NCT05748600 is a clinical study titled "A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma". The purpose of this study is to evaluate dexpramipexole as an add-on oral therapy in participants with inadequately controlled eosinophilic asthma to evaluate improvements in lung function, asthma control, and quality of life. In addition, the study will further evaluate the safety and tolerability ...
What is the current status of trial NCT05748600?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 600 participants. The study started on 2023-01-30. Estimated completion is 2025-12.
What conditions does trial NCT05748600 study?
This clinical trial studies the following conditions: Asthma Attack, Eosinophilic Asthma, Asthma; Eosinophilic.
What interventions are being tested in trial NCT05748600?
The interventions under investigation include: Placebo (DRUG), Dexpramipexole Dihydrochloride (DRUG).
Who is sponsoring clinical trial NCT05748600?
This trial is sponsored by Areteia Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05748600 being conducted?
This trial has 20 study locations across Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma Attack
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Wearable Electronic Breath Sound Sensing Device
RECRUITING
-
Timely Administration of IV Magnesium Sulfate in Patients With a Moderate Asthma Exacerbation
RECRUITING · Early Phase 1
-
Individualizing Treatment for Asthma in Primary Care (Full Study)
RECRUITING · Phase 4
-
User-Friendly Spirometer and Mobile App for Self-Management and Home Monitoring of Asthma Patients
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.